European Archives - European Medical Journal

Once-Weekly Injection Outperforms Daily Insulin in Type 2 Diabetes

Once-weekly IcoSema improved HbA1c and body weight more than daily insulin glargine in Type 2 diabetes.

Deep Learning Detects Valvular Heart Disease with High Accuracy

A systematic review and meta-analysis found deep learning models achieved high sensitivity and specificity for valvular heart disease detection on echocardiography.

Top-Down Therapy in Crohn’s Disease Linked to Improved 5-Year Outcomes

Five-year PROFILE follow-up linked early top-down therapy in Crohn’s disease with fewer surgeries, hospital admissions and stricturing or penetrating disease than step-up treatment.

Aneurysm Treatment Timing Fails to Show Clear Benefit

A systematic review of 11,096 records found earlier aneurysm repair reduced pretreatment rebleeding after aSAH, while evidence linking treatment timing to mortality and functional outcomes remained uncertain.

T-Cell Profiles Reveal New Insights into Childhood EoE

Distinct T-cell populations were linked to disease activity and treatment response in children with EoE.

Genetic Embryo Testing Shows No Live Birth Advantage with Donor Eggs

PGT-A did not reduce embryo transfers or time to live birth among recipients of donor oocytes.

Closeup of a person's eye with glaucoma

Air Pollution Linked to Higher Glaucoma and Cataract Risk: ESCRS 2026

Higher exposure to air pollution was associated with an increased risk of developing glaucoma and cataract.

beta-blockers, myocardial infarction, heart attack, cardiovascular disease, secondary prevention, heart failure

Stopping Beta-Blockers Years After Heart Attack May Be Safe

Stopping beta-blockers years after myocardial infarction was non-inferior to continued treatment in stable patients.

COVID-19-related hospitalisations autoimmune rheumatic conditions

Booster Vaccines Cut COVID-19 Hospitalisations in Rheumatic Disease

A US cohort study of 60,980 patients found that booster COVID-19 vaccines significantly lowered hospitalisation risk in rheumatic conditions.

efgartigimod pemphigus treatment

Efgartigimod Shows No Clinical Benefit in Pemphigus

A phase III trial found no clinical benefit from efgartigimod plus prednisone over prednisone alone in moderate-to-severe pemphigus.